Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer

AKIRA TAKEUCHI, TETSUYA OGURI, YORIKO YAMASHITA, KAZUKI SONE, SATOSHI FUKUDA, OSAMU TAKAKUWA, TAKEHIRO UEMURA, KEN MAENO, KENSUKE FUKUMITSU, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, YUTAKA ITO and AKIO NIIMI
Anticancer Research September 2018, 38 (9) 5489-5495; DOI: https://doi.org/10.21873/anticanres.12882
AKIRA TAKEUCHI
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUYA OGURI
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
2Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t-oguri@med.nagoya-cu.ac.jp
YORIKO YAMASHITA
3Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI SONE
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI FUKUDA
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OSAMU TAKAKUWA
4Department of Education and Research Center for Advanced Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKEHIRO UEMURA
5Department of Respiratory Medicine, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN MAENO
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENSUKE FUKUMITSU
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO KANEMITSU
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTSUGU OHKUBO
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYA TAKEMURA
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTAKA ITO
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIO NIIMI
1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and Methods: We retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(−)) or with bevacizumab (Bev(+)), and investigated the relationship between expression of TTF-1 and treatment outcomes. Results: Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(−) group (response rate, 51.4% vs. 27.3%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(−) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. Conclusion: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.

  • TTF-1
  • cisplatin
  • carboplatin
  • pemetrexed
  • bevacizumab

Thyroid transcription factor-1 (TTF-1) is a homeodomain-containing transcription factor, that is essential for the morphogenesis and differentiation of the thyroid, lung, and ventral forebrain. TTF-1 controls the expression of select genes in the thyroid, lung, and the central nervous system. In the lung, TTF-1 regulates the expression of surfactant proteins that are essential for lung stability and lung host defense (1). Expression of TTF-1 has been documented in neoplasms arising from cells that normally produce this transcription factor. Furthermore, TTF-1 is a lineage-survival oncogene in lung adenocarcinoma (2).

TTF-1 has been used widely as a diagnostic marker for primary and metastatic lung cancer, and, in particular, for identification of lung as the primary site of metastatic adenocarcinoma. Among primary non-small-cell lung cancers (NSCLC), TTF-1 immunoreactivity was significantly correlated with lung adenocarcinoma, but not with squamous cell carcinoma (3). Also, TTF-1 expression was recently shown to be a good prognostic factor of survival of NSCLC patients who received cytotoxic chemotherapy or EGFR-TKIs (4-6).

Vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in angiogenesis and is a promising target for cancer drug development. Anti-VEGF therapy, including bevacizumab, is therefore a major therapeutic option for targeting angiogenesis, especially in the context of advanced non-squamous (NS)-NSCLC (7, 8). However, biomarkers that help predict the efficacy of add-on bevacizumab therapy to cytotoxic agent chemotherapy in patients with NS-NSCLC are yet to be identified. In this study, we retrospectively examined the efficacy of addition of bevacizumab to platinum drugs and pemetrexed chemotherapy in patients with NS-NSCLC. Furthermore, we also investigated whether TTF-1 expression may serve as a predictive marker for addition of bevacizumab to platinum drugs and pemetrexed chemotherapy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A flow chart of total cases, excluded cases and treatment regimen of eligible cases. CDDP: Cisplatin; PEM: pemetrexed; CBDCA: carboplatin; Bev: bevacizumab.

Patients and Methods

Patients and chemotherapy. We retrospectively identified patients with advanced NS-NSCLC who were treated with or without the addition of bevacizumab to platinum derivatives and pemetrexed therapy at the Nagoya City University Hospital (Japan) between October 2009 and May 2017. Patients received four to six cycles of bevacizumab (Bev) (15 mg/kg) and/ or cisplatin (CDDP) (75 mg/m2) or carboplatin (CBDCA) (Area Under Curve [AUC] 5) and pemetrexed (PEM) (500 mg/m2). Patients who achieved complete response (CR), partial response (PR), or stable disease after induction therapy also received maintenance therapy (pemetrexed or pemetrexed plus bevacizumab) to the extent possible in. Both therapies were continued until detection of progressive disease (PD) or development of intolerable toxicity. Dose reduction or interruption was permitted in case of treatment-related toxicity. Our Institutional Ethics Committee approved the protocol of the study (IRB number: 1115), and all medical data were anonymized.

Immunohistochemical analysis of TTF-1 expression in NS-NSCLC. We used NS-NSCLC tissue samples obtained at the time of diagnosis from surgery, bronchoscopy, or computed tomography-guided biopsy. All samples were paraffin-embedded and 2-4 μm thick sections were prepared. Antigen retrieval was performed by autoclaving the sections at 97°C for 20 min in citrate buffer (pH 6.0). The sections were then incubated with mouse monoclonal anti-TTF-1 antibody clone 8G7G3/1 (Dako, Santa Clara, CA, USA, 1/100 dilution) for 2 h at room temperature. Primary antibody binding to the tissue sections was detected using EnVision FLEX kit (DAKO, Agilent). A pathologist (Y.Y.) and a pulmonologist (A.T.) who were blinded to the clinical information reviewed the immunostained sections, which were considered as positive when cytoplasmic or nuclear staining was evident.

Statistical analysis. Response rate (RR) was defined as the sum of CR and PR rate. RR was compared using the Fisher's exact test and p<0.05 was considered as statistically significant. Progression-free survival (PFS) was defined as the time from the first day of chemotherapy to the date of disease progression, death, or most recent follow-up. Overall survival (OS) was defined as the time from the first day of chemotherapy to the day of death or most recent follow-up. PFS and OS were analyzed using the Kaplan–Meier method and compared using the log-rank test. p<0.05 was considered as statistically significant. Multivariate analysis using a Cox proportional hazards model was performed to identify the association between clinical characteristics and survival. In this analysis, a probability of p=0.10 in the log-rank test was the threshold for the addition or removal of a covariable from the model, and p<0.05 again was considered as significant. All statistical analyses were performed with EZR (Saitama Medical center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics (9).

Results

We screened Stage IIIA, IIIB or IV NSCLC patients who were treated at the Nagoya City University Hospital between October 2009 and May 2017. Total of 277 patients were enrolled in the study, and they were all not indicated for curative radiotherapy. One hundred fifty-nine patients were excluded; 26 patients chose best supportive care, and 133 patients received other cytotoxic treatment regimens. The remaining 118 patients were reviewed. They were all performance status 0 or 1 and received chemotherapy: CDDP/PEM, CBDCA/PEM, CDDP/PEM/ Bev, or CBDCA/PEM/ Bev (Figure 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patients characteristics.

The clinicopathological characteristics of 118 patients are shown in Table I. Presence of epidermal growth factor receptor (EGFR) mutation in patients with TTF-1-positive NS-NSCLC was significantly higher than that in the TTF-1 negative group. Patients treated with bevacizumab added on pemetrexed and platinum derivatives (Bev(+) regimen) exhibited significantly higher RR compared with those treated with pemetrexed and platinum derivatives only (Bev(−) regimen) [47.7% vs. 25.7%, p=0.017]. PFS of patients treated with Bev(+) regimen was significantly longer than that of patients treated with Bev(−) regimen; however, no significant difference was observed with respect to OS [median PFS, 206 days vs. 137 days, p=0.028 (Figure 2A); median OS, 579 days vs. 420 days, p=0.475 (Figure 2B), respectively].

In patients with TTF-1-positive NS-NSCLC, use of Bev(+) regimen significantly improved the RR [51.4% vs. 27.3%, p=0.027]. Furthermore, Bev(+) regimen was associated with significantly prolonged PFS and a tendency for longer OS compared with that with Bev(−) regimen [median PFS, 216 days vs. 137 days, p=0.012 (Figure 3A); median OS, 646 days vs. 503 days, p=0.471 (Figure 3C), respectively]. On the other hand, in patients with TTF-1 negative NS-NSCLC, Bev(+) regimen did not show any clinical benefit over Bev(−) regimen [RR, 28.6% vs. 21.1%, p=1; median PFS 124 days vs. 131 days, p=0.374 (Figure 3B); median OS, 351 days vs. 354.5 days, p=0.543 (Figure 3D), respectively].

We performed univariate analysis to evaluate the influence of background characteristics on PFS of TTF-1 positive patients. The addition of bevacizumab and normal plasma level of cytokeratin 19 fragment (CYFRA 21-1) were associated with longer PFS (Table II). Finally, multivariate analysis was performed using the addition of bevacizumab, plasma levels of CYFRA 21-1 and carcinoembryonic antigen (CEA). Among the three covariables, only the addition of bevacizumab was a statistically significant factor [hazard ratio (HR), 0.54, p=0.011] (Table III).

Discussion

In this study, patients with TTF-1 positive NS-NSCLC who received Bev(+) regimen showed better RR and PFS as compared with those who received Bev(−) regimen. The clinical benefit of Bev(+) regimen in these patients was also shown on multivariate analysis. On the other hand, the antitumor effect of Bev(+) and Bev(−) regimens showed no significant difference in patients with TTF-1-negative NS-NSCLC. Our findings suggest that TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan−Meier curve of progression-free survival (A) and overall survival (B) in all non-squamous non-small cell lung cancer patients who received platinum doublet and bevacizumab or platinum doublet. Both curves were compared by log-rank test. C.I.: Confidence interval.

High expression of VEGF in NSCLC tissue is associated with poor prognosis (10). VEGF plays a key role in tumor proliferation by promoting tumor angiogenesis (11). Excess pro-angiogenic factors, including VEGF, induce abnormal tumor vessel formation, which results in tumor hypoxia and reduces the efficacy of anticancer treatment or irradiation (12). In addition, VEGF influences the tumor microenvironment by suppressing tumor-directed immune response (13). Bevacizumab, an anti-VEGF monoclonal antibody, not only suppresses and normalizes tumor vascularity but is also believed to re-engineer the tumor-immune microenvironment (14). Indeed, clinical trials have shown that the addition of bevacizumab improves the prognosis of patients with NS-NSCLC (7). Use of some biomarkers to predict the benefit of additional bevacizumab has been suggested in various cancers; these include, circulating endothelial progenitor cells in NSCLC (15), serum VEGF-A in breast cancer/pancreatic cancer/gastric cancer (16), and serum VEGF-D in colorectal cancer (17). However, these are preliminary findings, and their applicability to clinical practice is not clear. Our study suggests that TTF-1 expression in tumor tissues may potentially predict whether the addition of bevacizumab influences lung cancer treatment outcomes. VEGF promoter contains TTF-1 responsive elements, and TTF-1 positive cells have higher intracellular VEGF mRNA levels and secrete VEGF protein as compared with TTF-1 negative cells; in addition, reduction in TTF-1 was shown to downregulate these functions (18). It may be possible that tumor TTF-1 expression level controls its VEGF level and results in good clinical outcomes.

TTF-1 expression in NSCLC is known as a good prognostic factor for survival (19). However, the underlying mechanism of this correlation is not well understood. In normal lungs, TTF-1 is mainly expressed in alveolar type II and Clara epithelial cells and is a potential lineage-survival oncogene (2). TTF-1 expression has been shown to correlate with adenocarcinoma rather than squamous cell carcinoma (20). Although most lung adenocarcinomas express TTF-1, the frequency of TTF-1 expression in invasive mucinous adenocarcinoma (IMA), formerly mucinous bronchioloalveolar carcinoma, is lower than that in invasive non-mucinous adenocarcinoma (INMA) (21). Adenocarcinoma was categorized as terminal respiratory unit (TRU) type and non-TRU type, and IMAs are considered as non-TRU type, unlike many INMAs (22). TRU and non-TRU types exhibit differences with respect to expression of several genes which are associated with prognosis (23). TTF-1 expression in adenocarcinoma was proposed as a lineage marker of TRU (24); therefore, it is possible that TTF-1 positive and negative lung adenocarcinoma originate from different cellular lineages. This may influence the cellular proliferation pattern and sensitivity to chemotherapy, which results in different outcomes.

In this study, we assessed the efficacy of bevacizumab added to only pemetrexed and platinum combination therapy. Previously we have shown that serum cytokeratin 19 fragment (CYFRA 21-1) level is a predictive and prognostic marker of pemetrexed and platinum combination therapy in NS-NSCLC (25). CYFRA 21-1 is a specific marker of lung histological type of squamous cell carcinoma (26) which does not show a survival advantage with pemetrexed treatment (27); this suggests that elevated levels of serum CYFRA 21-1 indicate the presence of squamous cell components. Furthermore, we have also shown that CYFRA 21-1 predicts the efficacy of EGFR tyrosine kinase inhibitor treatment in patients with EGFR mutation-positive lung cancer (28). EGFR mutation is specific for TRU-type adenocarcinoma, which is often associated with TTF-1 expression (29). Collectively, these results and the findings from the present study suggest that the addition of bevacizumab would improve the prognosis of NS-NSCLC patients who are more sensitive to pemetrexed-containing chemotherapy, rather than improve poor prognosis.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Kaplan–Meier curve of Progression free survival (A, B) and overall survival (C, D) in thyroid transcription factor-1 positive (A, C) or negative (B, D) non-squamous non-small cell lung cancer patients who received platinum doublet and bevacizumab or platinum doublet. Both curves were compared by log-rank test. TTF-1: Thyroid transcription factor-1; C.I.: confidence interval.

Some limitations of this study need to be acknowledged. First, since this is a retrospective, single institute study, our results may be affected by selection bias. Clinical outcomes were almost similar to those in previous reports (30, 31), so we think the bias will not significantly influence the result. Second, the number of TTF-1 negative patients were quite lower than that of TTF-1 positive patients; therefore, the effect of additional bevacizumab may have been underestimated in the former group. However, the positivity rate of TTF-1 in primary pulmonary adenocarcinoma was shown to be 86% (3); therefore, the difference in the number of cases is acceptable. Third, TTF-1 is mainly expressed in primary lung cancer; we cannot use this method to predict whether bevacizumab may be effective in the context of other cancers.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate analysis about PFS in TTF-1-positive patients.

In conclusion, TTF-1 expression may predict favorable outcomes with the addition of bevacizumab therapy to platinum derivatives. Immunohistochemical analysis for TTF-1 expression in NSCLC is commonly used; therefore, this method is useful in many institutes to predict whether bevacizumab produces superior outcomes or not. Further validation with use of more rigid and larger controls is warranted.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Multivariate analysis about PFS in TTF-1 positive patients.

Acknowledgements

This work was presented in Rapid Abstract Poster Discussion Session at the American Thoracic Society (ATS) 2018 International Conference, May 18-23, in San Diego, California.

Footnotes

  • Conflicts of Interest

    The Authors declare no conflicts of interest regarding this study.

  • Received July 2, 2018.
  • Revision received July 19, 2018.
  • Accepted July 20, 2018.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Boggaram V
    : Thyroid transcription factor-1 (TTF-1/nkx2.1/titf1) gene regulation in the lung. Clin Sci (Lond) 116(1): 27-35, 2009.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tanaka H,
    2. Yanagisawa K,
    3. Shinjo K,
    4. Taguchi A,
    5. Maeno K,
    6. Tomida S,
    7. Shimada Y,
    8. Osada H,
    9. Kosaka T,
    10. Matsubara H,
    11. Mitsudomi T,
    12. Sekido Y,
    13. Tanimoto M,
    14. Yatabe Y,
    15. Takahashi T
    : Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 67(13): 6007-6011, 2007.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Stenhouse G,
    2. Fyfe N,
    3. King G,
    4. Chapman A,
    5. Kerr KM
    : Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 57(4): 383-387, 2004.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Berghmans T,
    2. Mascaux C,
    3. Martin B,
    4. Ninane V,
    5. Sculier JP
    : Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer 52(2): 219-224, 2006.
    OpenUrlCrossRefPubMed
    1. Gronberg BH,
    2. Lund-Iversen M,
    3. Strom EH,
    4. Brustugun OT,
    5. Scott H
    : Associations between TS, TTF-1, FR-alpha, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol 8(10): 1255-1264, 2013.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chung KP,
    2. Huang YT,
    3. Chang YL,
    4. Yu CJ,
    5. Yang CH,
    6. Chang YC,
    7. Shih JY,
    8. Yang PC
    : Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest 141(2): 420-428, 2012.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sandler A,
    2. Gray R,
    3. Perry MC,
    4. Brahmer J,
    5. Schiller JH,
    6. Dowlati A,
    7. Lilenbaum R,
    8. Johnson DH
    : Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24): 2542-2550, 2006.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Barlesi F,
    2. Scherpereel A,
    3. Rittmeyer A,
    4. Pazzola A,
    5. Ferrer Tur N,
    6. Kim JH,
    7. Ahn MJ,
    8. Aerts JG,
    9. Gorbunova V,
    10. Vikstrom A,
    11. Wong EK,
    12. Perez-Moreno P,
    13. Mitchell L,
    14. Groen HJ
    : Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: Avaperl (mo22089). J Clin Oncol 31(24): 3004-3011, 2013.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kanda Y
    : Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3): 452-458, 2013.
    OpenUrlCrossRefPubMed
  9. ↵
    1. O'Byrne KJ,
    2. Koukourakis MI,
    3. Giatromanolaki A,
    4. Cox G,
    5. Turley H,
    6. Steward WP,
    7. Gatter K,
    8. Harris AL
    : Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82(8): 1427-1432, 2000.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bremnes RM,
    2. Camps C,
    3. Sirera R
    : Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and BFGF in tumours and blood. Lung Cancer 51(2): 143-158, 2006.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Carmeliet P,
    2. Jain RK
    : Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6): 417-427, 2011.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Ott PA,
    2. Hodi FS,
    3. Buchbinder EI
    : Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5: 202, 2015.
    OpenUrlPubMed
  13. ↵
    1. Huang Y,
    2. Goel S,
    3. Duda DG,
    4. Fukumura D,
    5. Jain RK
    : Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73(10): 2943-2948, 2013.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Sudo K,
    2. Sato K,
    3. Sakamoto S,
    4. Hasegawa Y,
    5. Asano M,
    6. Okuda Y,
    7. Takeda M,
    8. Sano M,
    9. Watanabe H,
    10. Shioya T,
    11. Ito H
    : Association between endothelial progenitor cells and treatment response in non-squamous non-small cell lung cancer treated with bevacizumab. Anticancer Res 37(10): 5565-5571, 2017.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Jayson GC,
    2. Hicklin DJ,
    3. Ellis LM
    : Antiangiogenic therapy--evolving view based on clinical trial results. In: Nat Rev Clin Oncol England, pp. 297-303, 2012.
  16. ↵
    1. Lieu CH,
    2. Tran H,
    3. Jiang ZQ,
    4. Mao M,
    5. Overman MJ,
    6. Lin E,
    7. Eng C,
    8. Morris J,
    9. Ellis L,
    10. Heymach JV,
    11. Kopetz S
    : The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8(10): e77117, 2013.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wood LW,
    2. Cox NI,
    3. Phelps CA,
    4. Lai SC,
    5. Poddar A,
    6. Talbot C Jr..,
    7. Mu D
    : Thyroid transcription factor 1 reprograms angiogenic activities of secretome. Sci Rep 6: 19857, 2016.
    OpenUrl
  18. ↵
    1. Barlesi F,
    2. Pinot D,
    3. Legoffic A,
    4. Doddoli C,
    5. Chetaille B,
    6. Torre JP,
    7. Astoul P
    : Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 93(4): 450-452, 2005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tan D,
    2. Li Q,
    3. Deeb G,
    4. Ramnath N,
    5. Slocum HK,
    6. Brooks J,
    7. Cheney R,
    8. Wiseman S,
    9. Anderson T,
    10. Loewen G
    : Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34(6): 597-604, 2003.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wu J,
    2. Chu PG,
    3. Jiang Z,
    4. Lau SK
    : Napsin a expression in primary mucin-producing adenocarcinomas of the lung: An immunohistochemical study. Am J Clin Pathol 139(2): 160-166, 2013.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Sumiyoshi S,
    2. Yoshizawa A,
    3. Sonobe M,
    4. Kobayashi M,
    5. Sato M,
    6. Fujimoto M,
    7. Tsuruyama T,
    8. Date H,
    9. Haga H
    : Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Lung Cancer 84(3): 281-288, 2014.
    OpenUrl
  22. ↵
    1. Takeuchi T,
    2. Tomida S,
    3. Yatabe Y,
    4. Kosaka T,
    5. Osada H,
    6. Yanagisawa K,
    7. Mitsudomi T,
    8. Takahashi T
    : Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 24(11): 1679-1688, 2006.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Yatabe Y,
    2. Mitsudomi T,
    3. Takahashi T
    : Ttf-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26(6): 767-773, 2002.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Sone K,
    2. Oguri T,
    3. Nakao M,
    4. Kagawa Y,
    5. Kurowaka R,
    6. Furuta H,
    7. Fukuda S,
    8. Uemura T,
    9. Takakuwa O,
    10. Kanemitsu Y,
    11. Ohkubo H,
    12. Takemura M,
    13. Maeno K,
    14. Ito Y,
    15. Sato H,
    16. Muramatsu H,
    17. Niimi A
    : CYFRA 21-1 as a predictive marker for non-small cell lung cancer treated with pemetrexed-based chemotherapy. Anticancer Res 37(2): 935-939, 2017.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Pujol JL,
    2. Grenier J,
    3. Daures JP,
    4. Daver A,
    5. Pujol H,
    6. Michel FB
    : Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53(1): 61-66, 1993.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Scagliotti G,
    2. Hanna N,
    3. Fossella F,
    4. Sugarman K,
    5. Blatter J,
    6. Peterson P,
    7. Simms L,
    8. Shepherd FA
    : The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 14(3): 253-263, 2009.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Takeuchi A,
    2. Oguri T,
    3. Sone K,
    4. Ito K,
    5. Kitamura Y,
    6. Inoue Y,
    7. Asano T,
    8. Fukuda S,
    9. Kanemitsu Y,
    10. Takakuwa O,
    11. Ohkubo H,
    12. Takemura M,
    13. Maeno K,
    14. Ito Y,
    15. Niimi A
    : Predictive and prognostic value of CYFRA 21-1 for advanced non-small cell lung cancer treated with EGFR-TKIs. Anticancer Res 37(10): 5771-5776, 2017.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Yatabe Y,
    2. Kosaka T,
    3. Takahashi T,
    4. Mitsudomi T
    : EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29(5): 633-639, 2005.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Paz-Ares L,
    2. de Marinis F,
    3. Dediu M,
    4. Thomas M,
    5. Pujol JL,
    6. Bidoli P,
    7. Molinier O,
    8. Sahoo TP,
    9. Laack E,
    10. Reck M,
    11. Corral J,
    12. Melemed S,
    13. John W,
    14. Chouaki N,
    15. Zimmermann AH,
    16. Visseren-Grul C,
    17. Gridelli C
    : Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (paramount): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13(3): 247-255, 2012.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Patel JD,
    2. Socinski MA,
    3. Garon EB,
    4. Reynolds CH,
    5. Spigel DR,
    6. Olsen MR,
    7. Hermann RC,
    8. Jotte RM,
    9. Beck T,
    10. Richards DA,
    11. Guba SC,
    12. Liu J,
    13. Frimodt-Moller B,
    14. John WJ,
    15. Obasaju CK,
    16. Pennella EJ,
    17. Bonomi P,
    18. Govindan R
    : Pointbreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31(34): 4349-4357, 2013.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (9)
Anticancer Research
Vol. 38, Issue 9
September 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
AKIRA TAKEUCHI, TETSUYA OGURI, YORIKO YAMASHITA, KAZUKI SONE, SATOSHI FUKUDA, OSAMU TAKAKUWA, TAKEHIRO UEMURA, KEN MAENO, KENSUKE FUKUMITSU, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, YUTAKA ITO, AKIO NIIMI
Anticancer Research Sep 2018, 38 (9) 5489-5495; DOI: 10.21873/anticanres.12882

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
AKIRA TAKEUCHI, TETSUYA OGURI, YORIKO YAMASHITA, KAZUKI SONE, SATOSHI FUKUDA, OSAMU TAKAKUWA, TAKEHIRO UEMURA, KEN MAENO, KENSUKE FUKUMITSU, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, YUTAKA ITO, AKIO NIIMI
Anticancer Research Sep 2018, 38 (9) 5489-5495; DOI: 10.21873/anticanres.12882
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Keywords

  • TTF-1
  • cisplatin
  • Carboplatin
  • pemetrexed
  • bevacizumab
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire